Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution

European Journal of Immunology

Volumn 33, Issue 8, 2003, Pages 2123-2132

  Ma, Jun ^a,b   Urba, Walter J ^a   Si, Lüsheng ^b   Wang, Yili ^b   Fox, Bernard A ^a,c   Hu, Hong Ming ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Lymphopenia; Melanoma vaccine; Reconstitution; T lymphocyte

Indexed keywords

CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; HERMES ANTIGEN; PADGEM PROTEIN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG EFFICACY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HOMEOSTASIS; HOST; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHATIC DRAINAGE; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MEDICAL ASSESSMENT; MELANOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINATION; WHOLE BODY RADIATION;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNOLOGIC MEMORY; LYMPH NODES; LYMPHOCYTE DEPLETION; LYMPHOPENIA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; WHOLE-BODY IRRADIATION;

EID: 0041975925     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200324034     Document Type: Article

References (40)

1. Rosenberg, S. A., A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999. 10: 281-287.
2. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H. and White, D. E., Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 1998. 4: 321-327.
3. Mackall, C. L., Bare, C. V., Granger, L. A., Sharrow, S. O., Titus, J. A. and Gress, R. E., Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 1996. 156: 4609-4616.
4. Borrello, I., Sotomayor, E. M., Rattis, F. M., Cooke, S. K., Gu, L. and Levitsky, H. I., Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000. 95: 3011-3019.
5. Asavaroengchai, W., Kotera, Y. and Mule, J. J., Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl. Acad. Sci. USA 2002. 99: 931-936.
6. Hu, H. M., Poehlein, C. H., Urba, W. J. and Fox, B. A., Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002. 62: 3914-3919.
7. + T cells in lymphopenic hosts. Immunity 1999. 11: 183-190.
8. Goldrath, A. W., Bogatzki, L. Y. and Bevan, M. J., Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 2000. 192: 557-564.
9. + T cells: costimulatory requirements and role in memory formation. J. Immunol. 2001. 167: 3699-3707.
10. Murali-Krishna, K. and Ahmed, R., Cutting edge: naive T cells masquerading as memory cells. J. Immunol. 2000. 165: 1733-1737.
11. Cho, B. K., Rao, V. P., Ge, Q., Eisen, H. N. and Chen, J., Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 2000. 192: 549-556.
12. Dummer, W., Niethammer, A. G., Baccala, R., Lawson, B. R., Wagner, N., Reisfeld, R. A. and Theofilopoulos, A. N., T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 2002. 110: 185-192.
13. Surh, C. D. and Sprent, J., Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J. Exp. Med. 2000. 192: F9-F14.
14. + T cells in the absence of self peptide:MHC complexes. J. Immunol. 2000. 165: 2458-2464.
15. (+) lymphocytes convert to anergic or memory-like cells in T cell-deprived recipients. Eur. J. Immunol. 2001. 31: 2256-2265.
16. Rocha, B., Dautigny, N. and Pereira, P., Peripheral T lymphocytes: expansion potential and homeostatic regulation of pool sizes and CD4/CD8 ratios in vivo. Eur. J. Immunol. 1989. 19: 905-911.
17. Mackall, C. L., Hakim, F. T. and Gress, R. E., Restoration of T cell homeostasis after T cell depletion. Semin. Immunol. 1997. 9: 339-346.
18. Tanchot, C., Rosado, M. M., Agenes, F., Freitas, A. A. and Rocha, B., Lymphocyte homeostasis. Semin. Immunol. 1997. 9: 331-337.
19. Shevach, E. M., Suppressor T cells: rebirth, function and homeostasis. Curr. Biol. 2000. 10: R572-R575.
20. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10. J. Immunol. 2001. 166: 3008-3018.
21. Annacker, O., Burlen-Defranoux, O., Pimenta-Araujo, R., Cumano, A. and Bandeira, A., Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. J. Immunol. 2000. 164: 3573-3580.
22. Grossman, Z. and Singer, A., Tuning of activation thresholds explains flexibility in the selection and development of T cells in the thymus. Proc. Natl. Acad. Sci. USA 1996. 93: 14747-14752.
23. Surh, C. D. and Sprent, J., Regulation of naive and memory T cell homeostasis. Microbes Infect. 2002. 4: 51-56.
24. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 5211-5218.
25. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823-832.
26. (+) T cell-dependent immune defense of B16 melanoma. Cancer Res. 2001. 61: 8643-8646.
27. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001. 182: 18-32.
28. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J. Immunother. 2002. 25: 207-217.
29. + regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J. Immunol. 2002. 168: 5979-5983.
30. Ge, Q., Palliser, D., Eisen, H. N. and Chen, J., Homeostatic T cell proliferation in a T cell-dendritic cell coculture system. Proc. Natl. Acad. Sci. USA 2002. 99: 2983-2988.
31. Ganss, R., Ryschich, E., Klar, E., Arnold, B. and Hammerling, G. J., Combination of T cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 2002. 62: 1462-1470.
32. Guillaume, T., Rubinstein, D. B. and Symann, M., Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998. 92: 1471-1490.
33. Mackall, C. L., T cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells 2000. 18: 10-18.
34. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., Mavroukakis, S. A., White, D. E. and Rosenberg, S. A., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002. 298: 850-854.
35. Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., Young, N. S. and Barrett, A. J., Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 2000. 343: 750-758.
36. Cavazzana-Calvo, M., Andre-Schmutz, I., Hacein-Bey-Abina, S., Bensoussan, D., Le Deist, F. and Fischer, A., Improving immune reconstitution while preventing graft-versus-host disease in allogeneic stem cell transplantation. Semin. Hematol. 2002. 39: 32-40.
37. Childs, R. and Barrett, J., Nonmyeloablative stem cell transplantation for solid tumors: expanding the application of allogeneic immunotherapy. Semin. Hematol. 2002. 39: 63-71.
38. Luznik, L., Slansky, J. E., Jalla, S., Borrello, I., Levitsky, H. I., Pardoll, D. M. and Fuchs, E. J., Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 2003. 101: 1645-1652.
39. + T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 2000. 165: 4246-4253.
40. Hu, H. M., Urba, W. J. and Fox, B. A., Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 1998. 161: 3033-3041.